Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Conditions
- Small Lymphocytic LymphomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01699152
- Locations
- ๐บ๐ธ
GRU, Augusta, Georgia, United States
๐บ๐ธOSU, Columbus, Ohio, United States
๐บ๐ธMDACC, Houston, Texas, United States
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
- Conditions
- Blast CrisisAMLMultiple MyelomaALLMDS
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01204164
- Locations
- ๐บ๐ธ
MDACC, Houston, Texas, United States
๐บ๐ธRMCC, Denver, Colorado, United States
๐บ๐ธCornell, New York City, New York, United States
APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
- Conditions
- Pancreatic CancerMetastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT00709826
- Locations
- ๐บ๐ธ
The Queen's Medical Center Cancer Center, Honolulu, Hawaii, United States
๐บ๐ธFront Range Cancer Specialists, Ft. Collins, Colorado, United States
๐บ๐ธBronx River Medical Associates, P.C., Bronx, New York, United States
APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00657137
- Locations
- ๐บ๐ธ
UCLA, Los Angeles, California, United States
๐บ๐ธEastern Regional Medical Center, Philadelphia, Pennsylvania, United States
๐บ๐ธJabboury Foundation for Cancer Research Inc, Houston, Texas, United States
APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
- Conditions
- Recurrent Non Small Cell Lung Cancer
- Interventions
- Drug: apricoxib/erlotinibDrug: erlotinib/placebo
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2012-04-09
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT00652340
Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2010-03-17
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT00569114
- Locations
- ๐บ๐ธ
City of Hope, Duarte, California, United States
๐บ๐ธNevada Cancer Institute, Las Vegas, Nevada, United States
๐บ๐ธUniversity of Southern California, Los Angeles, California, United States